Cargando…
Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease
BACKGROUND: TreXTAM(® )is a combination of the key regulatory cytokine transforming growth factor beta (TGFβ) and all trans retinoic acid (ATRA) microencapsulated for oral delivery to immune structures of the gut. It is in development as a novel treatment for inflammatory bowel disease (IBD). AIM: T...
Autores principales: | Hammer, Laura, Furtado, Stacia, Mathiowitz, Edith, Auci, Dominick L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667406/ https://www.ncbi.nlm.nih.gov/pubmed/33251033 http://dx.doi.org/10.4292/wjgpt.v11.i5.79 |
Ejemplares similares
-
Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease
por: Lord, James D, et al.
Publicado: (2017) -
Effect of Tong Xie Yao Fang on endogenous metabolites in urine of irritable bowel syndrome model rats
por: Zhao, Xue-Ying, et al.
Publicado: (2019) -
Expression of Interleukin-26 is upregulated in inflammatory bowel disease
por: Fujii, Makoto, et al.
Publicado: (2017) -
Role of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease
por: Di Silvestre, Alessia, et al.
Publicado: (2019) -
Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease
por: Senhaji, Nezha, et al.
Publicado: (2017)